Nexara Health — Health Canada Drug Establishment Licence #3-002896

DEXIRON 50 MG

Last verified 2026-09-10 · Source: Health Canada Drug Product Database (DPD), DIN 02205963

DEXIRON 50 MG

IRON (IRON DEXTRAN COMPLEX) : 50 MG · DIN 02205963 · AMERICAN REGENT, INC

Health Canada status: CANCELLED POST MARKET

What is DEXIRON?

DEXIRON 50 MG contains IRON (IRON DEXTRAN COMPLEX) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02205963, held by AMERICAN REGENT, INC, supplied as SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 12-May-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is DEXIRON used for?

Treatment of documented iron deficiency in patients in whom oral iron administration is unsatisfactory or impossible.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02205963
Brand nameDEXIRON
Generic / active ingredientIRON (IRON DEXTRAN COMPLEX) : 50 MG
ManufacturerAMERICAN REGENT, INC
Strength50 MG
Dosage formSOLUTION
Route of administrationINTRAMUSCULAR ; INTRAVENOUS
SchedulePrescription
ATC codeB03AC IRON, PARENTERAL PREPARATIONS
AHFS class20:04.04
BiosimilarNo
Health Canada statusCANCELLED POST MARKET
Status date12-May-2022
Original market date1996-09-06 00:00:00

How is this product identified?

Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.

DIN (8-digit, as used in Nexara ordering)02205963
DIN (unpadded, as printed on some documents)2205963
Brand nameDEXIRON
Active ingredient / INNIRON (IRON DEXTRAN COMPLEX) : 50 MG
ATC codeB03AC
ATC anatomical main groupB — Blood and blood-forming organs
ATC therapeutic subgroupB03
AHFS class20:04.04
Health Canada schedulePrescription
Biosimilar biologicNo
Market authorization holderAMERICAN REGENT, INC

Health Canada approved product monograph (PDF)

How is it administered?

Discontinue oral iron. Administer 0.5 mL test dose first. IV: slow rate (max 1 mL/min). IM: Z-track technique into upper outer quadrant of buttock. Daily dose usually max 2 mL.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Store at room temperature, 15°-30°C (59°-86°F). Protect from excessive heat. Do not freeze.

How is it supplied?

2 mL single-dose vials supplied in cartons of 10 vials.

Which pack is which?

Strength on the label50 MG
Dosage formSOLUTION
RouteINTRAMUSCULAR ; INTRAVENOUS
Packaging as described in the monograph2 mL single-dose vials supplied in cartons of 10 vials.
StorageStore at room temperature, 15°-30°C (59°-86°F). Protect from excessive heat. Do not freeze.

One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Confirm the pack and get a price

Contraindications

Hypersensitivity to the drug product. All anemias not associated with iron deficiency.

Warnings and precautions

Serious hypersensitivity/fatal anaphylactic reactions reported. Use only where resuscitative equipment is available. Risk of injection site carcinogenesis. Avoid Total Dose Infusion (TDI).

What can be used instead?

Other Canadian products sharing ATC code B03AC IRON, PARENTERAL PREPARATIONS. 5 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
FERINJECT50 MGDISPERSIONVIFOR (INTERNATIONAL) INC.MARKETEDDIN 02546078
FERRLECIT12.5 MGSOLUTIONSANOFI-AVENTIS CANADA INCMARKETEDDIN 02243333
MONOFERRIC100 MGSOLUTIONPfizer Canada UlcMARKETEDDIN 02477777
PMS-IRON SUCROSE20 MGSOLUTIONPHARMASCIENCE INCMARKETEDDIN 02502917
VENOFER20 MGSOLUTIONFRESENIUS MEDICAL CARE CAN INCMARKETEDDIN 02243716
FERAHEME30 MGSOLUTIONAMAG PHARMACEUTICALS INCCANCELLED POST MARKETDIN 02377217
INFUFER50 MGLIQUIDSANDOZ CANADA INCORPORATEDCANCELLED POST MARKETDIN 02221780
JECTOFER 50 MG/ML100 MGLIQUIDASTRAZENECA CANADA INCCANCELLED POST MARKETDIN 00001910
TRIFERIC AVNU1.5 MGSOLUTIONROCKWELL MEDICAL INCCANCELLED PRE MARKETDIN 02515334

Can this still be bought in Canada?

No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.

If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Related pages

Sourcing this product